Video link

After years on the front lines of hospital oncology, Dr. Ray saw how often treatment decisions were guided by incomplete or non-predictive testing. Patients were routed to toxic, high-cost therapies that offered little chance of benefit because the available diagnostics could describe mutations but not tumor behavior. Choosing the right cancer drug often felt like throwing darts blindfolded…

STRATIFIND was born from his determination to close that gap – to take the guesswork out of Cancer Treatment with AI-driven Precision Oncology…

STRATIFIND’s proprietary Next Generation Sequencing (NGS)-based diagnostic paradigm serves to bring clinically actionable, biology-driven insight to the moment when the first treatment choice matters most.

Joining after Dr. Ray’s foundational research, Igor recognized that cancer science had moved beyond DNA-only profiling to RNA-driven multiomics, while diagnostics still relied on legacy tools. STRATIFIND aims to translate modern molecular science into a scalable, reimbursement-ready platform delivering the clinical insights patients should receive today.

STRATIFIND’s mission is embedded in its name: to stratify patient populations through clinically meaningful biomarkers and find those most likely to respond to a specific therapy. By matching tumor biology to the right treatment from the outset, the company aims to turn precision oncology from a descriptive exercise into a predictive, outcome-driven standard of care.

Our test name, RainDanceEQ™, draws on the symbolism of a rain dance – hope, renewal, and the promise of better outcomes – paired with "Dance," evoking DNA and RNA working in harmony. "EQ" encompasses what we bring to patients and physicians: Evidence, Empathy, Empowerment, and Elevated clinical insight. Together, STRATIFIND and RainDanceEQ reflect our goal of helping oncologists interpret complex tumor biology with greater clarity and clinical context.

To view even more information, please view our website at Stratifind.io.  

We believe cancer care today often answers only part of the patient’s most important questions. Many tests identify what therapies a patient may be eligible for, but do not fully address a broader hierarchy of needs — including expected outcomes, comparative effectiveness, and how treatments should be sequenced for the best possible result.

RainDanceEQ™ is designed to approach this challenge differently. By integrating DNA, RNA, and other biological and clinical signals, we aim to generate a more comprehensive view of each patient’s disease. This multi-omic approach is intended to help move beyond eligibility alone toward more informed treatment prioritization. 

Our platform is built with the perspective that patient needs should drive technology — not the other way around. We believe this approach positions RainDanceEQ™ at a critical point in the clinical decision process, where insights may support more personalized and potentially more effective treatment strategies.

Foundational R&D complete:

Proprietary platform being built:

• Algorithms developed using 20,000+ tumor samples
• 15+ years of foundational research
• 4 initial cancer indications - Lung, Breast, Colon and Melanoma
• Discovery, development and validation of core predictive algorithms completed for our first four cancer indications.

Clinical Workflow Integration:

The RainDanceEQ™ DNA+ RNA Next Generation Sequencing (NGS) test has been designed to bypass the typical delays encountered in oncology test workflow and improve efficiency, increase cost-effectiveness and offer comprehensive information that enables more accurate therapy guidance decision support. This Precision Oncology tool strives to empower Oncologists to make more confident treatment recommendations.

RainDanceEQ™ Fits Into the Real-World Cancer Decision Process

Cancer treatment decisions occur at several points as a patient moves from diagnosis through surgery and therapy planning. RainDanceEQ™ is designed to integrate into this existing workflow by analyzing tumor DNA and RNA to provide additional biological context when tissue becomes available.

Physicians often evaluate factors such as tumor aggressiveness, treatment sequencing, and recurrence risk when determining care plans. RainDanceEQ™ is intended to support these evaluations by providing multi-omic tumor information.

The platform can be ordered at two common clinical decision points.

Biopsy stage (before surgery). After diagnosis, tumor boards often review biopsy results to guide the initial treatment strategy.

Post-surgical stage. If surgery occurs first, tumor tissue may be analyzed to inform recurrence risk assessment and post-surgical therapy planning.

Because it can be used at multiple points in the care pathway, RainDanceEQ™ fits within existing oncology workflows without requiring a single ordering window.

RainDanceEQ™ is designed to transform complex tumor biology into clear, actionable treatment guidance. By integrating DNA mutations, RNA expression, and clinical context, our multi-omic intelligence platform moves beyond simply listing what therapies are possible to helping prioritize what should be used first. Each layer of our system builds toward a single goal: delivering clinically meaningful insights that support better decisions for patients and physicians. Below, you’ll see a mock of a critical page from the RainDanceEQ report depicting outputs from our predictive algorithms. These reports are designed to fit seamlessly into clinical workflows, enabling oncologists to quickly understand tumor behavior and identify the most relevant therapeutic strategies.

Each layer of our system builds toward a single goal: delivering clinically meaningful insights that support better decisions for patients and physicians. Below, you’ll see a mock of a critical page from the RainDanceEQ report depicting outputs from our predictive algorithms.

These reports are designed to fit seamlessly into clinical workflows, enabling oncologists to quickly understand tumor behavior and identify the most relevant therapeutic strategies.

Precision Oncology Report:

Molecular report architecture finalized, integrating algorithmic outputs with literature-anchored interpretation of biomarkers, pathways, and mutations.

Reimbursement strategy defined:

Clear day-one billing pathway identified based on established coding frameworks to support initial commercial deployment.

Bioinformatics infrastructure complete:

End-to-end analysis and report-generation pipeline in place and ready for bioinformatics validation in lung cancer, with breast cancer validation planned to follow as datasets are finalized.

Bringing Advanced and Novel Diagnostics to the Lab

Wet-lab partnership in discussion:

Discussions underway with CLIA-certified laboratories to select a CLIA Lab partner to support a seamless tissue-to-data-to-report workflow. This structure allows STRATIFIND to leverage established laboratory infrastructure while focusing on its proprietary analytics and reporting platform. Finalization of a partner agreement would enable clinical deployment without the capital intensity of building a traditional wet lab.

CLIA Dry-Lab implementation in progress:

Establishment of a Florida-based CLIA framework targeted for completion by the end of 2026, enabling a scalable data-to-report model, including billing, data re-analysis, and structured report delivery for patients with existing sequencing data.

Next-generation sequencing (NGS) has become a routine part of diagnostics of cancer. STRATIFIND sits on top of this existing testing infrastructure and converts molecular data into treatment decisions, creating a large and rapidly scalable market.

RainDanceEQ™ Operations Workflow

Following biopsy and shipment to the Wet Lab, DNA and RNA are extracted and prepared for sequencing. The sequencing data are then analyzed in the Dry Lab and a clinical report is generated.

Clinical validation in progress:

Lung cancer results being prepared for publication and submission to major oncology meetings (e.g., ASCO, ESMO, IASLC) in collaboration with Mass General physicians.

Validation and Clinical Evidence Plan

STRATIFIND's RainDanceEQ™ test is being developed as a laboratory-developed test (LDT) to be performed in a CLIA-certified laboratory.

As part of this process, we plan to complete a comprehensive analytical validation to confirm the test’s performance, including accuracy, consistency, and reliability using clinical samples.

At the same time, our proprietary algorithms have been developed and refined using large-scale datasets, including TCGA, as well as retrospective analyses of datasets generated through prior prospective clinical studies. These efforts support the clinical relevance of the signals incorporated into our reports.

Following validation, we plan to continue building clinical evidence through real-world use and additional retrospective and observational studies to support physician adoption and demonstrate clinical utility.

As is typical for LDTs, clinical validation is supported through a combination of analytical validation and evidence derived from retrospective datasets and real-world use, rather than prospective clinical trials.

All validation and evidence-generation activities will be conducted under the oversight of qualified laboratory leadership in accordance with CLIA requirements

We are still treating cancer with trial and error in an age when science can tell us far more.

Today’s standard tests read DNA. DNA is the genomic blueprint. It tells doctors what drugs can be used because a mutation is present. But it does not show how the tumor is actually behaving right now. RNA is the transcriptomic signal. It shows which pathways are turned on, which ones are quiet, and which therapy the cancer is most likely to respond to first.

Mutations tell you what you can give. RNA tells you what you should give first.

The problem is that the diagnostics industry is still built for the DNA-only era. So patients often receive toxic, expensive therapies that their tumor was never likely to respond to, while the signal that could guide the right first treatment already exists in the data.

This is frustrating for everyone involved. Patients want the right drug the first time. Doctors want a clear answer, not another 40-page mutation list. Payers are spending billions on therapies that do not work for the people getting them. Science has moved forward. Clinical decision tools have not.

That gap between what we know and what we do is the problem STRATIFIND was created to solve.

STRATIFIND aims to help doctors choose the right cancer treatment the first time.

We take the same tumor data that is already being generated in modern care and turn it into a clear, action-oriented answer: which therapy is most likely to work first, which ones are unlikely to help, and why.

Most tests stop at DNA and produce a long list of mutations. That tells you what drugs are possible.

STRATIFIND goes further. We read the RNA signals as well and combine multiple layers of biology. This multi-omic approach shows how the tumor is actually behaving right now. Then our evidence-based, clinically validated proprietary algorithms translate that biology into a ranked treatment strategy that a doctor can use immediately.

Instead of trial and error, the physician gets a roadmap. For patients, the potential impact is very real and very human:

• a better chance of getting an effective therapy sooner
• fewer months lost on treatments that were never likely to work
• fewer unnecessary side effects
• more time living normal life

For oncologists, it means clarity and confidence at the most important decision point. For payers, it means avoiding the enormous cost of ineffective drugs.

STRATIFIND is designed to work within the existing healthcare system, using established laboratory infrastructure and reimbursement pathways to support broader access. Our goal is simple: help translate complex tumor biology into clearer treatment decisions when they matter most.

STRATIFIND is a B2B2C precision oncology platform. Patients receive the test, physicians order it, laboratory partners run the sequencing, and we deliver the clinical intelligence that drives the treatment decision.

Because STRATIFIND operates primarily at the data interpretation and reporting layer rather than the laboratory layer, the model is designed to achieve higher margins and scale efficiently as test volume grows.

How it works: A patient’s tumor biopsy is sent to a CLIA-certified lab for next-generation sequencing. The molecular data is securely transferred to STRATIFIND, where our proprietary algorithms analyze the multi-omic signals and generate a clear, ranked therapy report. That report goes back to the oncologist and becomes part of the real treatment plan.

How we plan to get paid: We plan to bill Medicare and commercial insurance from day one using established reimbursement pathways. We believe that no new FDA approvals are required to begin commercial operations, and in our view our plans are aligned with existing CMS frameworks. Each clinically actionable report is planned to be billed with the goal to generate revenue.

Asset-Light and Scalable: STRATIFIND does not plan to build or own wet laboratories. Sequencing is expected to be performed by partner labs, while STRATIFIND focuses on data interpretation, reporting, and billing. This structure is intended to reduce capital needs and support broader expansion.

Go-to-Market Strategy: The test is expected to be marketed through a mix of direct relationships and distribution partners. Direct engagement may include oncologists, cancer centers, health systems, payors, and oncology care networks. Channel partnerships may include genomic test distributors, laboratory networks, integrated care providers, and international diagnostic partners.

Global Opportunity: Beyond insured patients in the U.S., the company may pursue additional opportunities such as cash-pay markets in Europe and Asia, where patients often seek advanced cancer decision tools.

Economic Model: STRATIFIND focuses on the clinical decision layer of the oncology workflow, emphasizing data interpretation and clinical insight. This model is designed to support scalable growth across cancers, geographies, and healthcare systems.

Barriers to Entry: STRATIFIND’s defensibility comes from a potential multi-layer platform advantage spanning data, clinical intelligence, physician workflow, and scientific validation.

Data Foundation: Our predictive models are trained on more than 20,000 tumor samples collected over more than a decade of research. This dataset forms the biological foundation of our algorithms and may present a meaningful barrier for new entrants attempting to replicate similar training data

Clinical Intelligence Layer: RainDanceEQ™ integrates DNA mutations, copy-number signals, and RNA expression into a unified interpretation designed to help physicians evaluate potential treatment implications across therapies such as chemotherapy, immunotherapy, and radiation.

Physician Workflow Integration: Cancer treatment decisions are commonly made in multidisciplinary tumor boards. Once a diagnostic test becomes part of that process, it often remains embedded in clinical workflow as physicians continue ordering tools that provide consistent clinical insight.

Scalable Operating Model: STRATIFIND plans to partner for wet-lab sequencing with intent of centralizing bioinformatics, reporting, and billing. This model could potentially enable scaling of software and interpretation while leveraging existing laboratory infrastructure.

Evidence Engine: Adoption in oncology is often supported by peer-reviewed studies, clinical validation, and presentations at scientific conferences, which can help build physician awareness and trust over time.

Despite significant scientific breakthroughs in cancer treatment, early detection and a trend of healthier habits, Cancer remains one of the largest and fastest-growing segments in healthcare, with ~2 million new cases in the U.S. in 2025.

Go-to-Market Approach

We are rolling out in three focused stages, expanding cancer by cancer where treatment selection is complex, high-cost, and clinically impactful.

TAM (Total Addressable Market) The total annual revenue opportunity if RainDanceEQ™ were adopted across all eligible cancer patients globally, assuming full market penetration across all indications, care settings, and geographies without competitive or operational constraints.

SAM (Serviceable Addressable Market) The portion of the TAM that RainDanceEQ™ can realistically serve based on current regulatory positioning, reimbursement pathway, lab capacity, geographic focus, and targeted cancer indications during the initial commercialization phase.

Stage 1

Lung, Breast, Colon, Melanoma

• TAM: ~400,000 tests/year → ~$1.0B
• SAM: ~220,000 tests/year → ~$550M

These are among the most genomically tested and therapeutically complex cancers, allowing immediate integration into existing clinical workflow and reimbursement at ~$2,500 per test.

Stage 2 – Major volume expansion

Adds Prostate + selective Radiation Therapy decision support

• TAM: ~630,000 tests/year → ~$1.58B
• SAM: ~380,000 tests/year → ~$950M

This stage significantly increases reach by entering one of the largest cancer populations in the U.S. and expanding into treatment-sequencing decisions for radiation therapy.

Stage 3 – Full multi-cancer platform

Adds Kidney (RCC), Liver (HCC), Bladder, Head & Neck

• TAM: ~860,000 tests/year → ~$2.15B
• SAM: ~540,000 tests/year → ~$1.35B

At this point, STRATIFIND becomes a broad, multi-indication precision oncology platform addressing the majority of high-value solid tumors.

Why this market is growing

• Biomarker-driven therapies are now standard of care
• Tumor sequencing is already widely reimbursed and performed
• Oncologists face an explosion of treatment options
• Payers are demanding value-based drug selection

The takeaway

With an average reimbursable price of ~$2,500 per test, a staged cancer-by-cancer rollout, and access to data that is already being generated in routine care, STRATIFIND is targeting a $1.0B initial market expanding to ~$2.1B in the U.S. alone, with clear clinical need and strong structural tailwinds.

Importantly, reimbursement strategy remains dynamic. As additional clinical utility data are generated, STRATIFIND may pursue PLA or other dedicated coding pathways designed to better reflect the platform’s differentiated value and potentially support higher reimbursement. Any such strategy would require further validation and payer engagement and is not included in current base-case projections.

Stratifind brings together three practicing physicians with deep clinical expertise, complemented by leadership in healthcare finance and healthcare operations and marketing. This combination positions us to align clinical insight with economic value and accelerate real-world adoption across healthcare systems.

Partha S. Ray, M.D.

Co-Founder, Chairman & Chief Medical Officer

Dr. Ray is a surgical oncologist with more than 15 years of frontline cancer care experience and over 5,000 complex tumor surgeries. After participating in more than 500 tumor boards, he saw firsthand how limited diagnostic tools often led to suboptimal treatment decisions, which became the founding motivation for STRATIFIND. He has spent over a decade researching predictive biomarkers across datasets exceeding 20,000 patient samples, focusing on how gene expression can guide therapy selection. At STRATIFIND, he leads clinical strategy, assay development, and scientific validation, ensuring the platform directly solves real-world decision problems for oncologists and patients. His career bridges daily cancer care and next-generation diagnostics, aligning the company’s mission with true clinical need. Dr. Ray received his MD with Honors from MCP Hahnemann College of Medicine in Philadelphia, Pennsylvania, completed his General Surgery Residency at University of Medicine and Dentistry of New Jersey in New Brunswick, New Jersey, pursued fellowship training in Advanced/Complex Surgical Oncology at the John Wayne Cancer Institute in Santa Monica, California and served on the faculty in the Department of Surgery at The University of Illinois College of Medicine in Urbana-Champaign.

Vision alignment: Dr. Ray’s goal is simple and personal — give physicians the tools he wished he had in the operating room and tumor board when treatment decisions mattered most.

Igor Sokolovsky

Co-Founder & Chief Executive Officer

Igor brings more than 20 years of healthcare investment banking and strategic advisory experience, with over $170 billion in completed transactions across diagnostics, life sciences, biopharma and healthcare services. Through his work with both emerging innovators and global industry leaders, he saw that the science of multi-omic cancer prediction had advanced far beyond what patients were actually receiving in clinical practice. As Founder of Barclay Street Advisors and former senior banker at Moelis, Guggenheim, and Citi, he combines capital markets expertise with deep sector knowledge. At STRATIFIND, he leads corporate strategy, reimbursement, partnerships, operations, and commercialization, building a scalable, asset-light platform that can bring modern precision oncology to everyday care. Igor received his Bachelor of Science degree from Leonard N. Stern School of Business at New York University, and his MBA from The Wharton School at University of Pennsylvania.

Vision alignment: Igor’s focus is translating breakthrough science into a reimbursed, globally scalable solution so patients can access the right therapy without waiting for the system to catch up.

Unique Founder Market Fit

STRATIFIND is built on a rare combination of a physician with experience treating thousands of cancer patients and guiding complex treatment decisions for hundreds, and a Wall Street banker with two decades of experience scaling and financing healthcare innovation. That partnership ensures the company is solving a real clinical problem and doing it in a way that can be reimbursed, deployed, and grown globally.

Dr. Ray brings firsthand knowledge of where current diagnostics fail patients and how oncologists actually make decisions in tumor boards and operating rooms. His research background turns that experience into a scientifically rigorous, clinically actionable product. Igor brings the complementary skill set required to translate breakthrough science into a sustainable business — capital strategy, partnerships, market access, and operational execution — with a track record of more than $170 billion in completed healthcare transactions.

Together, this creates a closed loop from biology → clinical utility → reimbursement → scale, which is where most diagnostics companies struggle.

Both founders are driven by the same goal: to end trial-and-error oncology by giving every patient access to a clear, predictive treatment roadmap. That shared mission, combined with deep domain expertise on both the medical and commercial sides, positions STRATIFIND to move faster and with more capital efficiency than traditional lab-centric models.

Pathology & Laboratory Medicine

Yury Takhalov, M.D., FCAP, FRCPC

Laboratory Medical Director

Dr. Takhalov is a board-certified pathologist with extensive clinical experience across surgical pathology, cytopathology, and laboratory medicine. He has worked in both academic and high-volume clinical laboratory settings, with a focus on delivering accurate, timely diagnostic insights that directly inform patient care. His experience spans multidisciplinary environments where pathology serves as the foundation for treatment decision-making across oncology and other disease areas. At STRATIFIND, he serves as Laboratory Medical Director, overseeing clinical validation, laboratory operations, quality systems, and the integration of multi-omic testing into real-world diagnostic workflows. His leadership ensures that RainDanceEQ™ outputs are grounded in rigorous pathology standards and aligned with clinical practice. Dr. Takhalov brings a strong background in quality assurance, laboratory accreditation, and diagnostic oversight, supporting the development of a scalable, compliant testing platform. Strategic impact: Anchors STRATIFIND’s platform in clinical laboratory rigor and regulatory alignment, enabling scalable deployment of multi-omic testing within real-world diagnostic and oncology workflows.

Dr. Takhalov earned his M.D. from the Sackler School of Medicine at Tel Aviv University (New York State/American Program) and holds a B.S. from Long Island University. He completed residency training in Anatomic and Clinical Pathology at Stony Brook University Medical Center, followed by fellowship training in Surgical Pathology at the University of Illinois at Chicago and Cytopathology at The Ohio State University Wexner Medical Center. He is board-certified by the American Board of Pathology in Anatomic and Clinical Pathology and Cytopathology, and is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC). Dr. Takhalov holds active medical licenses in multiple U.S. states, including New York, Florida, New Jersey, Connecticut, and Arizona. Dr. Takhalov earned his M.D. from the Sackler School of Medicine at Tel Aviv University (New York State/American Program) and holds a B.S. from Long Island University. He completed residency training in Anatomic and Clinical Pathology at Stony Brook University Medical Center, followed by fellowship training in Surgical Pathology at the University of Illinois at Chicago and Cytopathology at The Ohio State University Wexner Medical Center. He is board-certified by the American Board of Pathology in Anatomic and Clinical Pathology and Cytopathology, and is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC). Dr. Takhalov holds active medical licenses in multiple U.S. states, including New York, Florida, New Jersey, Connecticut, and Arizona.

Luke C. Peng, M.D., ScM

Advisory Board Member – Radiation Oncology & Multimodality Care

Dr. Peng is a radiation oncologist with academic and clinical leadership experience focused on integrating advanced diagnostics into real-world treatment planning. He has worked extensively in multidisciplinary tumor board settings where surgery, systemic therapy, and radiation decisions must be sequenced correctly for each patient. At STRATIFIND, he advises on clinical adoption, tumor board integration, and the expansion of RainDanceEQ™ into radiation-informed treatment pathways. His guidance ensures the platform delivers actionable insight at the exact point where complex multimodality decisions are made. Dr. Peng received his MD from Joan and Sanford I. Weill Medical College at Cornell University, completed an internship at Maimonides Medical Center, completed his residency at the Johns Hopkins University School of Medicine and is serving as Assistant Professor on the faculty of the Harvard Medical School.

Strategic impact: Positions STRATIFIND to participate in radiation therapy decision-making, expanding both clinical utility and total addressable market while embedding the platform directly into daily oncology workflow.

Michael Wentzien

Advisory Board Member – Reimbursement & Market Access Strategy

Michael Wentzien is a former senior managed care and healthcare services executive with deep expertise in payer strategy, reimbursement, and national contracting. He has spent his career on the side of the organizations that ultimately decide which technologies get covered, adopted, and scaled. At STRATIFIND, he advises on market access, distribution strategy, and payer-aligned commercialization, ensuring the platform is positioned to demonstrate clear economic value in value-based oncology models. His perspective strengthens the company’s ability to secure coverage, build strategic partnerships, and accelerate revenue growth.

Strategic impact: Aligns STRATIFIND’s clinical value with payer economics, which is the key driver of rapid adoption and long-term defensibility in precision oncology.

Our Advisory Board Brings Expert Leadership to Support Our Mission

These advisors extend STRATIFIND’s capabilities into two of the hardest and most important areas in oncology:

• Real-world treatment sequencing across multiple modalities (including radiation)
• Reimbursement, payer adoption, and national-scale distribution

Together, they help ensure that STRATIFIND is not just scientifically differentiated, but clinically embedded, reimbursed, and commercially scalable.

STRATIFIND is focused on bringing deeper molecular insight into everyday oncology care so physicians can better evaluate therapy options. Our goal is to help make complex tumor biology more useful at the moment treatment decisions are made.